SUPN
Supernus Pharmaceuticals, Inc. NASDAQ Listed May 1, 2012$52.29
Mkt Cap $3.0B
52w Low $30.44
74.7% of range
52w High $59.68
50d MA $50.98
200d MA $47.94
P/E (TTM)
-70.4x
EV/EBITDA
66.3x
P/B
2.5x
Debt/Equity
0.0x
ROE
-3.6%
P/FCF
61.0x
RSI (14)
—
ATR (14)
—
Beta
0.73
50d MA
$50.98
200d MA
$47.94
Avg Volume
691.5K
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
9715 Key West Avenue · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.28 | 0.60 | +115.0% | 49.19 | +3.0% | +4.6% | +1.6% | — | — | — | — |
| Feb 24, 2026 | AMC | 0.28 | 0.92 | +228.6% | 53.30 | +6.0% | +5.7% | -1.0% | -1.8% | +0.7% | -1.0% | — |
| Nov 4, 2025 | AMC | 0.82 | 1.01 | +23.2% | 57.00 | -21.6% | -17.4% | +0.3% | -2.6% | -1.3% | +1.6% | — |
| Aug 5, 2025 | AMC | 0.47 | 0.91 | +93.6% | 37.53 | +4.3% | +13.1% | -2.3% | -0.6% | -1.6% | +1.7% | — |
| May 6, 2025 | AMC | 0.38 | 0.42 | +10.5% | 32.43 | -7.4% | -4.6% | +1.9% | +0.5% | +1.4% | +0.4% | — |
| Feb 25, 2025 | AMC | 0.46 | 0.75 | +63.0% | 32.81 | +2.4% | -2.7% | -0.5% | +0.9% | -1.0% | -0.3% | — |
| Nov 4, 2024 | AMC | 0.39 | 1.06 | +171.8% | 34.70 | +13.5% | +0.1% | +8.7% | -3.6% | +0.5% | +0.0% | — |
| Aug 6, 2024 | AMC | 0.31 | 0.36 | +16.1% | 27.88 | +10.7% | +14.5% | -1.4% | +2.0% | +0.9% | +3.9% | — |
| May 8, 2024 | AMC | 0.38 | 0.26 | -31.6% | 31.30 | +0.7% | -4.2% | -3.5% | +2.5% | -2.4% | -0.8% | — |
| Feb 27, 2024 | AMC | 0.41 | 0.02 | -95.1% | 30.69 | -6.9% | +1.3% | -4.4% | +4.4% | -1.2% | -0.9% | — |
| Nov 8, 2023 | AMC | 0.13 | -0.29 | -323.1% | 23.52 | +6.3% | +11.1% | +2.0% | +2.6% | +2.6% | +2.0% | — |
| Aug 8, 2023 | AMC | 0.23 | -0.02 | -108.7% | 32.91 | -1.2% | -7.2% | +4.1% | +0.3% | -1.6% | +1.5% | — |
| May 9, 2023 | AMC | 0.17 | 0.29 | +70.6% | 36.18 | +2.3% | +1.5% | -2.2% | -4.9% | +1.8% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 | Stifel | Maintains | Hold → Hold | — | $49.28 | $48.90 | -0.8% | +4.5% | +0.0% | +0.4% | +0.1% | -0.4% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $50.67 | $51.07 | +0.8% | +2.7% | +1.6% | -0.2% | +0.9% | +4.7% |
| Oct 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $48.00 | $51.08 | +6.4% | +3.1% | -1.0% | -1.3% | +1.7% | +0.1% |
| Sep 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.60 | $48.01 | +0.9% | +0.4% | +0.5% | -0.2% | +0.8% | -0.1% |
| Aug 29 | Piper Sandler | Maintains | Neutral → Neutral | — | $45.37 | $45.58 | +0.5% | -0.6% | -1.3% | +0.9% | +1.1% | +1.3% |
| Aug 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.53 | $39.15 | +4.3% | +13.1% | -2.3% | -0.6% | -1.6% | +1.7% |
| Feb 26 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $32.81 | $33.59 | +2.4% | -2.7% | -0.5% | +0.9% | -1.0% | -0.3% |
| Feb 19 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $39.75 | $32.72 | -17.7% | -15.7% | +3.2% | -4.5% | -1.1% | +0.4% |
| Sep 11 | Piper Sandler | Downgrade | Overweight → Neutral | — | $33.49 | $32.71 | -2.3% | -7.2% | -0.6% | +0.7% | +1.2% | +0.8% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.69 | $28.58 | -6.9% | +1.3% | -4.4% | +4.4% | -1.2% | -0.9% |
| Nov 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.52 | $25.00 | +6.3% | +11.1% | +2.0% | +2.6% | +2.6% | +2.0% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $24.00 | $23.69 | -1.3% | -3.1% | -2.3% | +3.7% | +0.3% | +1.0% |
| May 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.18 | $37.00 | +2.3% | +1.5% | -2.2% | -4.9% | +1.8% | +1.2% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $40.31 | $40.70 | +1.0% | +2.2% | +0.6% | -0.9% | +0.0% | -0.9% |
| Aug 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.50 | $34.15 | +1.9% | +2.2% | +2.4% | -1.9% | -0.8% | +0.3% |
| Apr 13 | Jefferies | Upgrade | Hold → Buy | — | $27.97 | $29.81 | +6.6% | +11.9% | +1.9% | -0.1% | -0.5% | -2.4% |
| Jun 16 | Piper Sandler | Upgrade | Neutral → Overweight | — | $23.07 | $24.75 | +7.3% | +6.5% | -2.4% | -0.4% | -0.6% | +0.7% |
| Apr 16 | Stifel | Maintains | Hold → Hold | — | $18.86 | $18.86 | +0.0% | -0.8% | +6.3% | -11.2% | +3.5% | -0.8% |
| Nov 7 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $19.93 | $20.00 | +0.4% | +6.1% | +2.7% | +0.6% | -1.0% | +1.2% |
| Nov 7 | Stifel | Downgrade | Buy → Hold | — | $19.93 | $20.00 | +0.4% | +6.1% | +2.7% | +0.6% | -1.0% | +1.2% |
| Nov 6 | Jefferies | Downgrade | Buy → Hold | — | $29.13 | $21.96 | -24.6% | -31.6% | +6.1% | +2.7% | +0.6% | -1.0% |
| Dec 17 | Mizuho | Maintains | Buy → Buy | — | $35.76 | $36.00 | +0.7% | +0.2% | -2.3% | -4.7% | -1.5% | -5.6% |
| Nov 12 | B. Riley FBR | Maintains | Buy → Buy | — | $45.27 | $44.93 | -0.8% | -1.3% | +0.9% | -4.5% | +0.1% | +1.9% |
| Nov 12 | B. Riley Securities | Maintains | Buy → Buy | — | $45.27 | $44.93 | -0.8% | -1.3% | +0.9% | -4.5% | +0.1% | +1.9% |
| Aug 9 | Jefferies | Maintains | Buy → Buy | — | $48.70 | $48.65 | -0.1% | -1.2% | -4.1% | -5.7% | -1.8% | +1.3% |
| May 25 | Stifel Nicolaus | Maintains | Buy → Buy | — | $55.65 | $56.00 | +0.6% | +2.9% | -2.1% | +2.3% | -1.7% | +2.4% |
| May 25 | Stifel | Maintains | Buy → Buy | — | $55.65 | $56.00 | +0.6% | +2.9% | -2.1% | +2.3% | -1.7% | +2.4% |
| May 5 | B. Riley FBR | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 4 | Janney Montgomery Scott | Upgrade | Neutral → Buy | — | $37.20 | $38.85 | +4.4% | -0.1% | -0.1% | -1.8% | +3.0% | +1.6% |
| Dec 4 | Janney Capital | Upgrade | Neutral → Buy | — | $37.20 | $38.85 | +4.4% | -0.1% | -0.1% | -1.8% | +3.0% | +1.6% |
| Nov 8 | B. Riley FBR | Maintains | Buy → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Nov 8 | Stifel Nicolaus | Upgrade | Hold → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Nov 8 | Stifel | Upgrade | Hold → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Nov 8 | B. Riley Securities | Maintains | Buy → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Sep 19 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $49.65 | $44.70 | -10.0% | -23.4% | -3.4% | +7.2% | -1.0% | +0.3% |
| Sep 19 | Stifel | Downgrade | Buy → Hold | — | $49.65 | $44.70 | -10.0% | -23.4% | -3.4% | +7.2% | -1.0% | +0.3% |
| Jul 17 | Piper Sandler | Downgrade | Overweight → Neutral | — | $44.25 | $42.80 | -3.3% | -5.2% | +2.6% | +1.2% | -2.9% | -0.2% |
| Jul 17 | PiperJaffray | Downgrade | Overweight → Neutral | — | $44.25 | $42.80 | -3.3% | -5.2% | +2.6% | +1.2% | -2.9% | -0.2% |
| Jun 1 | Piper Sandler | Upgrade | Neutral → Overweight | — | $37.60 | $38.40 | +2.1% | +3.1% | +3.4% | -2.5% | +1.5% | +2.0% |
| Jun 1 | PiperJaffray | Upgrade | Neutral → Overweight | — | $37.60 | $38.40 | +2.1% | +3.1% | +3.4% | -2.5% | +1.5% | +2.0% |
| Aug 4 | Jefferies | Maintains | Buy → Buy | — | $22.92 | $23.44 | +2.3% | -2.6% | +3.5% | +0.4% | -0.1% | -1.9% |
| Jul 18 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| Jul 18 | PiperJaffray | Downgrade | Overweight → Neutral | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| Jul 18 | Northland Securities | Downgrade | Outperform → Market Perform | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| Jul 18 | Piper Sandler | Downgrade | Overweight → Neutral | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| May 12 | Jefferies | Maintains | Buy → Buy | — | $16.18 | $16.34 | +1.0% | +0.6% | +6.2% | +2.3% | +0.5% | -1.9% |
| Feb 8 | Jefferies | Upgrade | Hold → Buy | — | $12.13 | $12.24 | +0.9% | +3.4% | -3.3% | +2.9% | -1.0% | +3.9% |
| Jun 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
| Jun 18 | Stifel Nicolaus | Maintains | Buy → Buy | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
| Jun 18 | Jefferies | Upgrade | Hold → Buy | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
No insider trades available.
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report Q1 2026 earnings on May 5, 2026, with management hosting a conference call at 4:30 p.m. ET for investor updates.
Apr 22
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
SUPN completed a significant asset acquisition, potentially expanding its product portfolio or market reach and signaling management confidence in growth opportunities that could drive future revenue.
Apr 7
8-K · 5.02
!!! Very High
Supernus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Supernus Pharmaceuticals modified executive compensation packages approved by its board, likely affecting future operating costs and management incentive alignment for investors tracking operational expenses.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it contains only standard boilerplate forward-looking statement disclaimers without disclosing any specific business event, transaction, or material development affecting Supernus Pharmaceuticals investors.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report its 2025 financial results on February 24, 2026, followed by a management conference call at 4:30 p.m. ET.
Feb 12
8-K · 5.02
!!! Very High
Mitek Systems, Inc. -- 8-K 5.02: Executive Change
Mitek Systems appointed Eric Bell as Chief Accounting Officer, strengthening its accounting leadership team and potentially improving financial reporting oversight for investors.
Feb 5
Data updated apr 27, 2026 3:34am
· Source: massive.com